ASCLS eNewsBytes

• Antiretroviral Therapy Linked to Increased Diabetes Risk in HIV June 23, 2026
  Individuals with HIV face a significant burden from diabetes, as antiretroviral therapy exposure and longer treatment duration correlate with a higher incidence of this metabolic condition. With improvements in antiretroviral therapy enhancing survival rates, chronic comorbidities like diabetes have become crucial factors influencing long-term health outcomes.
• FDA Approves First Treatment for Chronic Hepatitis Delta Virus Infection June 23, 2026
  The U.S. Food and Drug Administration has approved Hepcludex injection for treating chronic hepatitis delta virus infection in adults without cirrhosis or compensated cirrhosis.
• Mold Infections Post Lung Transplant Double All-Cause Mortality Risk June 23, 2026
  Invasive mold infections following lung transplantation often lead to higher acute care usage and approximately double the mortality risk. A study evaluated the correlation between these infections in lung transplant recipients and their associated health care utilization, costs and mortality rates.
• Methylene Blue Enhances Hair Follicle Stem Cell Regeneration Under Stress June 23, 2026
  Methylene blue, a mitochondrial antioxidant, was studied for its effects on human hair follicle stem cells under oxidative and metabolic stress. These stem cells are crucial for hair growth but can be adversely affected by aging, UV radiation, oxidative stress and metabolic issues, leading to hair thinning and scalp aging.
• Early Recognition Challenges in Meningococcal Disease and the Role of Prevention June 23, 2026
  Researchers highlight the clinical challenge of meningococcal disease, which often starts with ambiguous flu-like symptoms such as fever, fatigue and headache, complicating early diagnosis. Patients can rapidly deteriorate within hours, facing severe complications and high mortality rates despite advanced ICU care.